Drugs / BAT2306
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04711343 | Jun 2022 → May 2023 | psoriasis | Bio-Thera Solutions | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT05377944 | Oct 2022 → May 2024 | psoriasis | Bio-Thera Solutions | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAT2306 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05377944 ↗ |
| Modality | Monoclonal antibody | “Recombinant human monoclonal antibody against IL-17A” NCT05377944 ↗ |
| Route | Subcutaneous | “150mg /1ml; subcutaneous injection” NCT04711343 ↗ |
| Target | IL17A | “Recombinant human monoclonal antibody against IL-17A” NCT05377944 ↗ |